Clinical Trials | March 05, 2026
During live demonstrations, industry leaders highlighted SEOPRO’s ability to spot portfolio risk, execution bottlenecks, and decision delays early—before they escalate into costly program disruptions
The facility is expected to become operational by FY2028-29
Lupin attained a score of 91 out of 100, establishing itself as the leading pharmaceutical company globally
The product addresses a market with approximately $66.8 million in annual sales as of December 2025.
Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
The approved product is a generic version of the reference listed drug (RLD) Lamictal ODT by GlaxoSmithKline and is indicated for the treatment of epilepsy and bipolar disorder
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
Subscribe To Our Newsletter & Stay Updated
